Assessment of the coagulation profile in hemato-oncological patients receiving ATG-based conditioning treatment for allogeneic stem cell transplantation

Bone Marrow Transplantation
A InbalA Nagler

Abstract

Antithymocyte globulin (ATG) is increasingly used in pre-allogeneic stem cell transplantation (allo-SCT) conditioning regimens to prevent graft rejection and graft-versus-host disease. However, ATG was also found to be associated with increased incidence of thrombosis during organ transplantation. In the present study, we tested the coagulation status of 21 patients with hematologic malignancies undergoing allo-SCT who received ATG-based (11 patients) or non-ATG-based (10) conditioning treatment. We assessed several thrombophilia markers as well as circulating total and endothelial microparticles (TMP/EMP) and soluble CD40 ligand (CD40L). No significant difference in the mean values of prothrombin time, partial thromboplastin time, fibrinogen, antithrombin, protein C, protein S, thrombin-antithrombin III complex, homocysteine levels, prevalence of genetic thrombophilia markers and levels of EMP, TMP or CD40L was observed between the ATG-treated and ATG-untreated patients, as well as before and after conditioning in each group separately. Platelet counts decreased significantly in ATG-treated patients; however, this decrease was not associated with clinical or laboratory evidence of disseminated intravascular coagulation. No pat...Continue Reading

References

Dec 4, 1992·Annals of the New York Academy of Sciences·H F DvorakD R Senger
Aug 20, 1970·The New England Journal of Medicine·T E StarzlC G Halgrimson
Jan 1, 1994·Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis·A FalangaT Barbui
Mar 1, 1996·Journal of Clinical Immunology·J E Buhlmann, R J Noelle
Sep 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G F von TempelhoffL Heilmann
May 1, 1997·The Journal of Clinical Investigation·O P BarryG A FitzGerald
Mar 12, 1999·Arteriosclerosis, Thrombosis, and Vascular Biology·O SalomonU Seligsohn
Jun 15, 2000·Immunological Investigations·A MigaR J Noelle
Jan 13, 2001·Journal of Thrombosis and Thrombolysis·J M WalengaH L Messmore
Jun 21, 2001·Blood Reviews·R HoffmanB Brenner

❮ Previous
Next ❯

Citations

Mar 16, 2007·British Journal of Haematology·Susan F Lynch, Christopher A Ludlam
May 15, 2015·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·A CumpelikD Zecher
Apr 12, 2006·Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis·Salih AksuSemra V Dundar

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.